MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2023 International Congress

    Olfactory dysfunction and neuropsychiatric manifestations in early drug-naïve Parkinson’s disease

    P. Julayanont (Phoenix, USA)

    Objective: To determine the severity of various neuropsychiatric disturbances in drug-naïve Parkinson’s disease (PD) patients with (PD-OD) and without olfactory dysfunction (PD-NOD) compared to healthy…
  • 2023 International Congress

    Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)

    M. Tosin, T. Mestre, G. Stebbins, G. Mangone, S. Videmsky, S. Ali, D. Aarsland, J. Goldman, T. Khoo, S. Lewis, P. Martinez-Martin, O. Ojo, J. Pagonabarraga, A. Schrag, D. Weintraub, C. Goetz (Chicago, USA)

    Objective: Present the development process and clinimetric testing plan for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Psychosis…
  • 2023 International Congress

    Clinico-genetic analysis of patients with Parkinson’s disease and GBA mutations from a tertiary care teaching centre in India

    S. Kamath, V. Holla, P. Phulpagar, N. Kamble, R. Yadav, B. Muthusamy, PK. Pal (Bangalore, India)

    Objective: To describe the clinico-genetic association of PD patients with heterozygous GBA mutations (PDwG). Background: Parkinson’s disease (PD) is currently understood to be the outcome…
  • 2023 International Congress

    Jumping to Conclusions bias, psychosis and impulsivity in early stages of Parkinson’s disease

    IP. Pachi, VP. Papadopoulos, CK. Koros, AMS. Simitsi, AB. Bougea, MB. Bozi, NP. Papagiannakis, RFP. Soldatos, DK. Kolovou, GP. Pantes, NS. Scarmeas, LAX. Xenaki, GP. Paraskevas, KV. Voumvourakis, SGP. Papageorgiou, KK. Kollias, NS. Stefanis, LS. Stefanis (Athens, Greece)

    Objective: The aim was to explore the correlations between Jumping to Conclusions (JtC) tendency and neuropsychiatric features in patients with early Parkinson’s disease (PD). Background:…
  • 2023 International Congress

    Clozapine Therapy for Parkinson’s Disease Psychosis: A 21-Year Service Analysis

    W. Woods, T. Payne, N. Hoyle, O. Bandmann (Sheffield, United Kingdom)

    Objective: To review the demographic aspects, safety, and efficacy of Clozapine treatment for Parkinson’s Disease Psychosis (PDP) in a large patient cohort. Background: The impact…
  • 2023 International Congress

    Quetiapine for the treatment of psychosis in dementia with Lewy bodies: a systematic review.

    M. Giusti, PL. Silva, G. Bolner, C. Menegon, MF. Felippe, G. Herwig, A. Rossato, EG. Almeida, M. Rosa, CR. Rieder (Porto Alegre, Brazil)

    Objective: Perform a systematic review of the literature about the efficacy of quetiapine in the treatment of psychosis in patients with Lewy’s Body Dementia. Background:…
  • 2023 International Congress

    Development of an Item Bank for Assessing Psychosis in Parkinson’s Disease: A Systematic Review

    G. Mangone, M. Tosin, C. Goetz, G. Stebbins, T. Mestre (Chicago, USA)

    Objective: This study aimed to develop an item bank for assessing psychosis in Parkinson's disease (PD). Background: Psychosis is a common and debilitating symptom in…
  • 2023 International Congress

    Safety assessment of pimavanserin in Parkinson’s disease psychosis patients: Evidence from a systematic review and meta-analysis of randomized controlled trials

    G. Bano, A. Sharma (New Delhi, India)

    Objective: This systematic review and meta-analysis aimed to assess the safety profile of pimavanserin in Parkinson’s disease psychosis (PDP) patients from the available randomized controlled…
  • 2023 International Congress

    Parkinson’s disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.

    H. Dourado, C. Lobo, G. Procópio, AE. Lima, MA. Silveira, L. de Almeida, IJ. Oliveira, G. Valença (Salvador, Brazil)

    Objective: To describe the prevalence of Parkinson's Disease (PD) associated psychosis (PDAP) at a Brazilian movement disorders outpatient and to evaluate its associated factors. Background:…
  • 2022 International Congress

    Alteration of lysosomal enzymatic activities in blood of patients with schizophrenia

    A. Bezrukova, K. Basharova, M. Nikolaev, E. Palchikova, I. Miliukhina, G. Baydakova, N. Zalutskaya, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To estimate whether alteration of lysosomal activities contributes to schizophrenia (SCZ) pathogenesis, age at onset and risk of developing the disease. Background: SCZ is…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley